Duration of protection by oxitropium bromide against cholinergic challenge.
In order to determine the duration of action of the inhaled anticholinergic agent oxitropium bromide, a controlled study of the effect of pre-treatment with oxitropium bromide 200 micrograms against cholinergic challenge was carried out in ten asthmatic subjects (6 children, 4 adults). After baseline measurements of lung function (FEV1 and sGaw) and methacholine PC20 (the concentration of methacholine to produce a 20% fall in FEV1) oxitropium bromide or placebo were inhaled double-blind on 2 separate days. Lung function and methacholine PC20 were then measured at 1, 3 and 6 h post dosing. Oxitropium bromide caused significant protection from methacholine challenge for 6 h (p less than 0.05).
Wilson
N M
NM
Department of Paediatrics and Neonatal Medicine, Hammersmith Hospital, London, UK.
Green
S
S
Coe
C
C
Barnes
P J
PJ
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001980:Bronchi / Q000187:drug effects; D002648:Child; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D016210:Methacholine Chloride; D008688:Methacholine Compounds / Q000494:pharmacology; D008875:Middle Aged; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use*; D010277:Parasympathomimetics / Q000494:pharmacology; D012129:Respiratory Function Tests; D012602:Scopolamine Derivatives / Q000494:pharmacology / Q000627:therapeutic use*
D008688:Methacholine Compounds; D010276:Parasympatholytics; D010277:Parasympathomimetics; D012602:Scopolamine Derivatives; D016210:Methacholine Chloride; C017590:oxitropium